Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 20 recruiting now full pipeline #83 of 28,707 conditions

Cardiovascular Disease: full-pipeline trial registry

20 of 138 indexed Cardiovascular Disease trials are currently recruiting.

Corpus placement: #83 of 28,707 conditions by registered trial count.

138 US clinical trials · 20 currently recruiting · #83 of 28,707 conditions by registered trial count

Cardiovascular Disease: 138 US clinical trials tracked, 20 recruiting.

Cardiovascular Disease is the subject of 138 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 22 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 10 of these trials.

Enrollment posture brief

Registry condition cardiovascular-disease

OPEN 20 | RECR 14% | LATE 22 | EARLY 15 | RANK #83 | SPON 10

Nearest open-share peer: Acute Coronary Syndrome (15% recruiting · 41 trials)

Metastatic Breast Cancer52.9%Myelodysplastic Syndrome34.1%Carcinoma, Non-Small Cell Lu32.3%Osteoarthritis21.3%Cardiovascular Disease (this)14%
Open-enrollment share among volume-matched conditions near Cardiovascular Disease

Cardiovascular Disease lists 20 open slots (14% of 138 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cardiovascular Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cardiovascular Disease is recruiting below its size-band peers.

    20 of 138 indexed trials (14.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cardiovascular Disease trials is spread across many organizations.

    VA Office of Research and Development accounts for 10 of 138 trials (7.2%). 84 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cardiovascular Disease enrolment sits around 120 participants.

    Median target enrolment is 120 among the 138 trials that report a genuine target (sentinel values excluded). 59 of those (42.8%) plan for fewer than 100 participants.

  4. Cardiovascular Disease splits between interventional and observational designs.

    93 interventional and 45 observational studies make up this index (67.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 28Phase 314Phase 48

Open and recent trials

138 total, page 3 of 3

COMPLETED NA 65 participants

PREVENT Tool Study: Late Effects Clinic

Washington University School of Medicine

NCT04530825

COMPLETED NA 64 participants

Mindfulness, Yoga, and Cardiovascular Disease

The Cleveland Clinic

NCT00696852

COMPLETED NA 61 participants

Effects of Almonds on Cardiovascular Risk Factors

Penn State University

NCT01101230

COMPLETED NA 60 participants

Soybean Oil Trial of cArdiovascular Risk

USDA Beltsville Human Nutrition Research Center

NCT02404207

COMPLETED NA 60 participants

Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol

The Cleveland Clinic

NCT01817491

COMPLETED 60 participants

The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

University of California, San Francisco

NCT00627068

COMPLETED Phase 2 58 participants

Biomarker Guided Therapies in Stage A/B Heart Failure

VA Office of Research and Development

NCT02230891

COMPLETED NA 58 participants

Star-Close Early Ambulation Trial

Ernest Mazzaferri

NCT00590798

COMPLETED NA 51 participants

PCI Alternative Using Sustained Exercise

VA Office of Research and Development

NCT03520400

COMPLETED 47 participants

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

National Human Genome Research Institute (NHGRI)

NCT01160536

COMPLETED NA 46 participants

Individual Variability to Aerobic Exercise Training

Western Colorado University

NCT02868710

COMPLETED NA 46 participants

Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors

Penn State University

NCT02210767

COMPLETED NA 44 participants

Exercise and Pioglitazone for HIV-Metabolic Syndromes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00639457

COMPLETED NA 43 participants

Quality Improvement and Personalization for Statins

VA Office of Research and Development

NCT02820870

COMPLETED NA 43 participants

Canola Oil Multicentre Intervention Trial (COMIT)

Penn State University

NCT01233778

COMPLETED Phase 4 43 participants

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

University of Pennsylvania

NCT02187172

COMPLETED NA 42 participants

Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk

Penn State University

NCT02557334

COMPLETED Phase 2 42 participants

The Fibrin Pad Cardiovascular Study

Ethicon

NCT01681030

COMPLETED NA 40 participants

IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial

The University of Texas Medical Branch, Galveston

NCT01869348

COMPLETED NA 40 participants

The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome

Christos Mantzoros

NCT00525629

COMPLETED NA 40 participants

STEP AND GO: A Study of Technology-based Exercise Promotion

The University of Texas Medical Branch, Galveston

NCT01953224

COMPLETED NA 39 participants

Change of Fructose to Fat in South Asians

The Rogosin Institute

NCT01562782

COMPLETED 38 participants

Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients

Washington University School of Medicine

NCT00501163

COMPLETED Phase 4 36 participants

MIcrovascular dysfuNction In Moderate-severe Psoriasis

Marcelo F. Di Carli, MD, FACC

NCT04271540

COMPLETED NA 32 participants

The Effect of Processed Tomato Products on CVD Risks

Penn State University

NCT00937742

COMPLETED NA 30 participants

Expression of Longevity Genes in Response to Extended Fasting

Intermountain Health Care

NCT01059760

COMPLETED 30 participants

Periodontal and Periapical Inflammation and Pregnancy

Roger Johnson

NCT00490165

COMPLETED NA 30 participants

Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program

University of Pittsburgh

NCT00867425

COMPLETED NA 24 participants

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

Creighton University

NCT01018849

COMPLETED NA 21 participants

Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome

University of Connecticut

NCT01411293

COMPLETED NA 20 participants

Healthy Fatty Acids in Transition

Penn State University

NCT00937963

COMPLETED NA 20 participants

The Effects Grapes on Health Indices

University of California, Davis

NCT01674231

COMPLETED Phase 1 20 participants

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Eli Lilly and Company

NCT01825889

COMPLETED NA 20 participants

Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults

Ohio State University

NCT02364570

COMPLETED NA 17 participants

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

University of Colorado, Denver

NCT02122198

COMPLETED Phase 1 15 participants

Fructose-Induced Palmitate Synthesis in Overweight Subjects

Rockefeller University

NCT00535535

COMPLETED 14 participants

Fat Biology, Sleep Disorders, and Cardiovascular Disease

Mayo Clinic

NCT01229501

COMPLETED Phase 2 11 participants

Trial of Oral Glutamine on Mitochondrial Function in CKD

University of Washington

NCT02838979

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 8
Phase 3 14
Phase 4 8

Named interventions

Most-linked intervention names on Cardiovascular Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
14 trials
Fish oil placebo Dietary supplement
2 trials
Vitamin D3 placebo Dietary supplement
2 trials
AZD0780 Drug
2 trials
Exercise Behavioral
2 trials
placebo Drug
2 trials
Placebo Other
2 trials
PREVENT Tool Other
1 trials

US sites by state

Facility locations filed on Cardiovascular Disease trials. A trial with sites in several states counts in each.

California 25 trials
Maryland 17 trials
Massachusetts 17 trials
Pennsylvania 13 trials
New York 13 trials
North Carolina 13 trials
Florida 12 trials
Texas 11 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cardiovascular Disease page

138 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiovascular Disease condition card totals 138 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.